Allschwil, Switzerland, September 24, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has initiated the Fosmanogepix Against Standard-of-care Treatment in Invasive Candidiasis (FAST-IC) phase 3 study. This registrational study evaluates the efficacy and safety of […]

Phase 3 PHOENYCS GO study met the primary endpoint demonstrating clinical improvement in moderate-to-severe systemic lupus erythematosus; Clinical improvements were observed among key secondary endpoints measuring disease activity and flares. UCB and Biogen are advancing dapirolizumab pegol with the objective to address the substantial unmet medical need for people living with SLE, where there are

BASEL, Switzerland, Sept. 24, 2024 (GLOBE NEWSWIRE) — BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (“MDR”) bacteria, in collaboration with its partners in the AMR Accelerator programme, call for sustainable investment in antimicrobial research and development. Antibiotic

Pratteln, Switzerland, September 24, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces that Swissmedic, the Swiss Agency for Therapeutic Products, has accepted for review the marketing authorization application (MAA) for AGAMREE(R) (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD). Santhera asked Swissmedic to assess AGAMREE(R) as part of Article 13 TPA (therapeutics product act) procedure,

STUTTGART, Germany, Sept. 24, 2024 (GLOBE NEWSWIRE) — On Sept. 18, a Chinese folk music concert named “Eternal Jiangnan” was held at Stuttgart, Germany. The concert, held by Jiangsu International Culture Association, featuring performers from east China’s Jiangsu Province, was a key event in the “Jiangsu Week of Chinese Folk Music”. At the same time,

NEW YORK, NY / ACCESSWIRE / September 24, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Adobe Inc. ("Adobe Inc.") (NASDAQ:ADBE) concerning possible violations of federal securities laws. Adobe issued a press release on September 12, 2024, reporting financial results for the third quarter of its fiscal year 2024.

NEW YORK, NY / ACCESSWIRE / September 24, 2024 / If you suffered a loss on your New Fortress Energy Inc. (NASDAQ:NFE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/new-fortress-energy-inc-lawsuit-submission-form?prid=104730&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

Milledgeville, Georgia, Sept. 24, 2024 (GLOBE NEWSWIRE) — Georgia College & State University, the state’s designated public liberal arts university, gained among the elite top 20 universities in the Regional South in U.S. News & World Report’s 2025 Best Colleges guidebook released today. Georgia College & State University ranks sixth in “Top Public Schools, Regional

NEW YORK, NY / ACCESSWIRE / September 24, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Rentokil Initial plc ("Rentokil Initial plc") (NYSE:RTO) concerning possible violations of federal securities laws. Rentokil disclosed on September 11, 2024, that it expected full-year adjusted pretax profit of approximately £700 million, compared to

NEW YORK, NY / ACCESSWIRE / September 24, 2024 / If you suffered a loss on your STMicroelectronics N.V. (NYSE:STM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/stmicroelectronics-lawsuit-submission-form?prid=104728&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)